ENLV has 36-month beta value of 1.02. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ENLV is 18.76M, and currently, short sellers hold a 0.53% ratio of that float. The average trading volume of ENLV on December 03, 2024 was 155.14K shares.
ENLV) stock’s latest price update
The stock of Enlivex Therapeutics Ltd (NASDAQ: ENLV) has increased by 10.19 when compared to last closing price of 1.08.Despite this, the company has seen a gain of 11.21% in its stock price over the last five trading days. accesswire.com reported 2024-11-26 that NESS ZIONA, ISRAEL / ACCESSWIRE / November 26, 2024 / Enlivex Therapeutics Ltd. (Nasdaq:ENLV)(the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, is pleased to invite investors to a webinar on December 3, 2024, at 11:00 a.m.
ENLV’s Market Performance
Enlivex Therapeutics Ltd (ENLV) has seen a 11.21% rise in stock performance for the week, with a -12.50% decline in the past month and a -3.25% plunge in the past quarter. The volatility ratio for the week is 9.04%, and the volatility levels for the past 30 days are at 10.17% for ENLV. The simple moving average for the past 20 days is 6.74% for ENLV’s stock, with a -33.70% simple moving average for the past 200 days.
Analysts’ Opinion of ENLV
Many brokerage firms have already submitted their reports for ENLV stocks, with H.C. Wainwright repeating the rating for ENLV by listing it as a “Buy.” The predicted price for ENLV in the upcoming period, according to H.C. Wainwright is $33 based on the research report published on March 02, 2021 of the previous year 2021.
ENLV Trading at -11.95% from the 50-Day Moving Average
After a stumble in the market that brought ENLV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.07% of loss for the given period.
Volatility was left at 10.17%, however, over the last 30 days, the volatility rate increased by 9.04%, as shares sank -3.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.86% lower at present.
During the last 5 trading sessions, ENLV rose by +17.76%, which changed the moving average for the period of 200-days by -62.05% in comparison to the 20-day moving average, which settled at $1.1183. In addition, Enlivex Therapeutics Ltd saw -55.93% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ENLV
The total capital return value is set at -0.64. Equity return is now at value -57.93, with -49.35 for asset returns.
Currently, EBITDA for the company is -28.22 million with net debt to EBITDA at 0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.71.
Conclusion
To put it simply, Enlivex Therapeutics Ltd (ENLV) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
